References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2024 · External reference

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

10.1007/s10549-020-05831-y · 2020 · External reference

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: the AMAZONA retrospective cohort study

10.1016/j.breast.2019.01.008 · 2019 · External reference

Targeting HER2-positive breast cancer: advances and future directions

10.1038/s41573-022-00579-0 · 2023 · External reference

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

10.1200/jco.2014.55.5730 · 2014 · External reference

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

10.1016/s0140-6736(13)61094-6 · 2013 · External reference

10.1158/1538-7445.sabcs15-s5-04

10.1158/1538-7445.sabcs15-s5-04 · 2016 · External reference

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

10.1016/s1470-2045(11)70336-9 · 2012 · External reference

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

10.1093/annonc/mdt182 · 2013 · External reference

Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3 years' median follow-up

10.1016/j.esmoop.2025.105112 · 2025 · External reference

Survival with trastuzumab emtansine in residual HER2-Positive breast cancer

10.1056/nejmoa2406070 · 2025 · External reference

Brazil's unified health system: the first 30 years and prospects for the future

10.1016/s0140-6736(19)31243-7 · 2019 · External reference

Challenge of incorporating new drugs for breast cancer in Brazil: a proposed framework for improving access to innovative therapies

10.1200/go.20.00566 · 2021 · External reference

Inequalities in unmet need for health care services and medications in Brazil: a decomposition analysis

2023 · External reference

Health technology assessment in the Brazilian National health System: profile of CONITEC exclusion recommendations, 2012-2023

10.1590/s2237-96222024v33e20240057.en · 2024 · External reference

Unresolved reference

2024 · External reference

Pertuzumab plus trastuzumab on the neoadjuvant treatment of her2-positive breast cancer: a cost analysis of recurrent disease on the brazilian public healthcare system

10.1016/j.jval.2019.04.257 · 2019 · External reference

The worldwide impact of HER2-targeted treatments in women with breast cancer: an epidemiological modeling study

2023 · External reference

Unresolved reference

2022 · External reference

Understanding the impact of socioeconomic differences in breast cancer survival in England and Wales: avoidable deaths and potential gain in expectation of life

10.1016/j.canep.2014.11.002 · 2015 · External reference

Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study

10.1016/s2214-109x(25)00494-2 · 2026 · External reference

Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-Positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update

10.1200/jco.23.02505 · 2024 · External reference

Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6

10.1016/j.jval.2012.04.014 · 2012 · External reference

Estimation of premature deaths from lack of access to Anti-HER2 therapy for advanced breast cancer in the Brazilian public health System

10.1200/jgo.2016.005678 · 2017 · External reference

Pertuzumab+trastuzumab treatment on her2+ early breast cancer: long-term reduction of metastasic breast cancer incidence in Argentina

2019 · External reference

Cost-Effectiveness analysis of adjuvant pertuzumab and trastuzumab in human epidermal growth factor receptor 2-Positive early breast cancer in Japan

10.1007/s40261-024-01399-3 · 2024 · External reference

Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States

10.1097/coc.0000000000000816 · 2021 · External reference

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

10.31744/einstein_journal/2022gs6655 · 2022 · External reference

Cost-Effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-Positive breast cancer in the United States

10.1016/j.jval.2018.11.014 · 2019 · External reference

Unresolved reference

2022 · External reference

Breast cancer survival and the health system in Brazil: an analysis of public and private healthcare

10.3389/fonc.2023.927748 · 2023 · External reference

Discrepancies in breast cancer's oncological outcomes between public and private institutions in the southeast region of Brazil: a retrospective cohort study

10.3389/fonc.2023.1169982 · 2023 · External reference